search
Back to results

Single Dose Study of BMS-820836

Primary Purpose

Depression

Status
Completed
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
BMS-820836
BMS-820836
BMS-820836
BMS-820836
BMS-820836
BMS-820836
BMS-820836
BMS-820836
BMS-820836
Placebo
BMS-820836
BMS-820836
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive and weight ≥ 50 kg
  • Right-handed, non-ambidextrous subjects for Part 2
  • Men and women, ages 18 to 55 years, inclusive

Exclusion Criteria:

  • Women of child bearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product
  • WOCBP using a prohibited contraceptive method
  • Women who are pregnant or breastfeeding
  • Sexually active fertile men not using effective birth control if their partners are WOCBP
  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • History of cholecystectomy
  • Any major surgery within 4 weeks of study drug administration
  • Any gastrointestinal surgery that could impact the absorption of study drug
  • Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration
  • Blood transfusion within 4 weeks of study drug administration
  • Inability to tolerate/swallow oral medication
  • Difficulty with venipuncture and/or poor venous access
  • Self-reported smokers
  • Recent (within 1 year) of psychostimulant use (cocaine, methylphenidate, amphetamines, ecstasy)
  • Confirmed resting supine systolic blood pressure > 130 mmHg
  • Confirmed resting supine diastolic blood pressure > 80 mmHg
  • Confirmed QT value ≥ 500 msec
  • Confirmed QTc (Bazett) value ≥ 450 msec
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
  • History of peppermint allergies
  • History of brain conditions (e.g. history of stroke, head trauma, etc.)
  • History of or current psychiatric conditions
  • History of claustrophobia

Sites / Locations

  • Local Institution

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

BMS-820836 (Part 1, Panel 1)

BMS-820836 (Part 1, Panel 2)

BMS-820836 (Part 1, Panel 3)

BMS-820836 (Part 1, Panel 4)

BMS-820836 (Part 1, Panel 5)

BMS-820836 (Part 1, Panel 6)

BMS-820836 (Part 1, Panel 7)

BMS-820836 (Part 1, Panel 8)

BMS-820836 (Part 1, Panel 9)

BMS-820836 (Part 2, Panel A)

BMS-820836 (Part 2, Panel B)

Arm Description

Outcomes

Primary Outcome Measures

To assess the safety and tolerability of BMS-820836 following single-dose administration

Secondary Outcome Measures

To assess the single-dose pharmacokinetics of BMS-820836 and its N-demethylated metabolite BMS-821007
To assess the pharmacodynamics of BMS-820836

Full Information

First Posted
August 24, 2009
Last Updated
January 24, 2011
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00964912
Brief Title
Single Dose Study of BMS-820836
Official Title
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
April 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BMS-820836 (Part 1, Panel 1)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 2)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 3)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 4)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 5)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 6)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 7)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 8)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 1, Panel 9)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 2, Panel A)
Arm Type
Active Comparator
Arm Title
BMS-820836 (Part 2, Panel B)
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 0.025 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 0.1 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 0.25 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 0.5 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 1 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 2 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 3 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 5 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 8 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral Solution, Oral, 0 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 3 mg, single dose, one dose
Intervention Type
Drug
Intervention Name(s)
BMS-820836
Intervention Description
Oral Solution, Oral, 0.5 mg, single dose, one dose
Primary Outcome Measure Information:
Title
To assess the safety and tolerability of BMS-820836 following single-dose administration
Time Frame
Within 14 days of first dose
Secondary Outcome Measure Information:
Title
To assess the single-dose pharmacokinetics of BMS-820836 and its N-demethylated metabolite BMS-821007
Time Frame
Within 7 days of dosing
Title
To assess the pharmacodynamics of BMS-820836
Time Frame
Within 48 hours of dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive and weight ≥ 50 kg Right-handed, non-ambidextrous subjects for Part 2 Men and women, ages 18 to 55 years, inclusive Exclusion Criteria: Women of child bearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product WOCBP using a prohibited contraceptive method Women who are pregnant or breastfeeding Sexually active fertile men not using effective birth control if their partners are WOCBP Any significant acute or chronic medical illness Current or recent (within 3 months) gastrointestinal disease History of cholecystectomy Any major surgery within 4 weeks of study drug administration Any gastrointestinal surgery that could impact the absorption of study drug Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration Blood transfusion within 4 weeks of study drug administration Inability to tolerate/swallow oral medication Difficulty with venipuncture and/or poor venous access Self-reported smokers Recent (within 1 year) of psychostimulant use (cocaine, methylphenidate, amphetamines, ecstasy) Confirmed resting supine systolic blood pressure > 130 mmHg Confirmed resting supine diastolic blood pressure > 80 mmHg Confirmed QT value ≥ 500 msec Confirmed QTc (Bazett) value ≥ 450 msec History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) History of peppermint allergies History of brain conditions (e.g. history of stroke, head trauma, etc.) History of or current psychiatric conditions History of claustrophobia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5V 2T3
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Single Dose Study of BMS-820836

We'll reach out to this number within 24 hrs